Press release
Seborrhoeic Dermatitis Clinical Trials | A Drug Pipeline Analysis Report 2024 | Arcutis Biotherapeutics, Cutanea Life Sciences, DermBiont, Astion Pharma A/S, Amorepacific
Seborrhoeic Dermatitis Clinical Trials
Download our sample report @ https://www.delveinsight.com/report-store/seborrhoeic-dermatitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Key Takeaways from the Seborrhoeic Dermatitis Pipeline Report
Over 5+ Seborrhoeic Dermatitis pipeline therapies are in various stages of development, and their anticipated acceptance in the Seborrhoeic Dermatitis market would significantly increase market revenue.
Leading Seborrhoeic Dermatitis companies developing novel drug candidates to improve the Seborrhoeic Dermatitis treatment landscape include Arcutis Biotherapeutics, Cutanea Life Sciences, DermBiont, Amorepacific, and others.
Promising Seborrhoeic Dermatitis pipeline therapies in various stages of development include Topical roflumilast foam (ARQ-154), Omiganan (CLS002), DBI-002, PAC-14028, and others.
Seborrhoeic Dermatitis Overview
Seborrheic dermatitis is a chronic inflammatory skin condition that typically affects areas of the body with a high density of sebaceous glands, such as the scalp, face, chest, back, armpits, and groin. It has been reported to affect about 4% of the population. The exact cause of seborrheic dermatitis is not fully understood, but it is believed to be triggered by the overgrowth of a harmless yeast called Malassezia, which lives on the skin, or an overreaction of the skin's immune system to this yeast.
Diagnosis is based on the location and appearance of the rash or lesion. A skin biopsy may be helpful for confirmation but is rarely indicated. Seborrheic dermatitis is managed with treatments that reduce the level of skin yeast, including creams and shampoos, which can be used safely on a long-term basis.
To know more about seborrhoeic dermatitis pipeline segment, visit: https://www.delveinsight.com/report-store/seborrhoeic-dermatitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Seborrhoeic Dermatitis Emerging Drugs
Topical roflumilast foam (ARQ-154): Arcutis Biotherapeutics
Topical roflumilast foam (ARQ-154) is a foam formulation of a highly potent and selective PDE4 inhibitor (roflumilast). Roflumilast has shown greater potency based on IC50 values (a non-clinical measure of a drug's potency) than any other disclosed PDE4 inhibitor. PDE4 is an intracellular enzyme that increases the production of pro-inflammatory mediators and decreases production of anti-inflammatory mediators and has been implicated in a wide range of inflammatory diseases. Arcutis has initiated a Phase 2 clinical trial to evaluate topical roflumilast foam for seborrheic dermatitis.
Omiganan (CLS002): Cutanea Life Sciences
Chitosan (CLS002), an implantable bioresorbable gel based on chitin and chitosan to treat soft tissue abnormalities of the skin. It is in phase II of clinical trials for the treatment of Seborrhoeic Dermatitis.
DBI-002: DermBiont
Mechanism of Action: Microbiome modulators. The drug is in preclinical studies for the treatment of Seborrhoeic Dermatitis.
PAC-14028: Amorepacific
PAC-14028 was developed as a transient receptor potential vanilloid type 1 (TRPV1) antagonist. It is known that TRPV1 might be deeply associated with skin permeability barrier function, suggesting that modulation of TRPV1 might be beneficial for the skin disorders with barrier damages. Amorepacific developed a topical cream formulation of PAC-14028. AC-14028 participated in phase II clinical trials to evaluate its safety and efficacy in seborrheic dermatitis
Discover more about the emerging Seborrhoeic Dermatitis drugs @ https://www.delveinsight.com/sample-request/seborrhoeic-dermatitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Seborrhoeic Dermatitis Key Companies
Arcutis Biotherapeutics
Cutanea Life Sciences
DermBiont
Amorepacific
Seborrhoeic Dermatitis Pipeline Therapies
Topical roflumilast foam (ARQ-154)
Omiganan (CLS002)
DBI-002
PAC-14028
Seborrhoeic Dermatitis Pipeline Therapeutics Assessment
By development stage
By product type
By route of administration
By molecule type
By MOA type
Scope of the Seborrhoeic Dermatitis Pipeline Report
Coverage: Global
Key Seborrhoeic Dermatitis Companies: Arcutis Biotherapeutics, Cutanea Life Sciences, DermBiont, Amorepacific, and others
Key Seborrhoeic Dermatitis Pipeline Therapies: Topical roflumilast foam (ARQ-154), Omiganan (CLS002), DBI-002, PAC-14028, and others
Find out more about the Seborrhoeic Dermatitis treatment options in development @ https://www.delveinsight.com/sample-request/seborrhoeic-dermatitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Trending Reports By DelveInsight:
Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market
Lebers Hereditary Optic Neuropathy Lhon Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market
Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market
Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market
Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market
Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market
Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market
Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market
Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market
Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market
Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market
Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market
Hypoplastic Left Heart Syndrome Hlhs Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market
Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market
Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market
Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market
Clinically Isolated Syndrome CIS Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market
Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market
Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market
Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market
Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market
Contact Us
Kritika Rehani
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Seborrhoeic Dermatitis Clinical Trials | A Drug Pipeline Analysis Report 2024 | Arcutis Biotherapeutics, Cutanea Life Sciences, DermBiont, Astion Pharma A/S, Amorepacific here
News-ID: 3631712 • Views: …
More Releases from DelveInsight Business Research LLP
Real World Evidence Solution Market is expected to rise at a CAGR of 8.07% by 20 …
The global real-world evidence (RWE) solutions market was valued at USD 2,832.33 million in 2024 and is projected to grow at a CAGR of 8.07% between 2025 and 2032, reaching USD 5,240.07 million by 2032. Market growth is primarily driven by the rising prevalence of chronic diseases and the increasing reliance on real-world data to understand their impact. Advancements in technologies such as big data analytics, artificial intelligence, and machine…
Gene Therapy Market is expected to rise at a CAGR of 19.25% by 2032, estimates D …
The global gene therapy market was valued at USD 8,570.28 million in 2024 and is projected to grow at a CAGR of 19.25% from 2025 to 2032, reaching USD 34,933.71 million by 2032. The increasing prevalence of genetic and rare diseases has fueled demand for innovative therapeutic solutions, positioning gene therapy as a key treatment option. This growth is further supported by an expanding pipeline of gene therapies, including numerous…
High Flow Oxygen Therapy Devices Market is expected to rise at a CAGR of 2.31% b …
The global high-flow oxygen therapy (HFOT) devices market is projected to expand at a CAGR of 2.31% between 2025 and 2032. Rising incidences of respiratory conditions such as COPD, asthma, pneumonia, and Acute Respiratory Distress Syndrome (ARDS) are driving demand for HFOT devices, as healthcare providers increasingly adopt non-invasive treatment options. At the same time, the growth of home healthcare and telemedicine is improving access to these devices, allowing patients…
Tumor Ablation Market is expected to rise at a CAGR of 13.3% by 2032, estimates …
The global tumor ablation market was valued at USD 1,703.26 million in 2024 and is projected to grow at a CAGR of 13.30% from 2025 to 2032, reaching USD 4,595.68 million by 2032. The increasing global burden of cancer is driving demand for effective treatment options such as tumor ablation. Rising adoption of minimally invasive procedures, due to benefits like reduced recovery times, lower complication risks, and cost efficiency compared…
More Releases for Seborrhoeic
Seborrhoeic Dermatitis Market Predicted to See Upsurge Through 2032, Highlights …
The Key Seborrhoeic Dermatitis Companies in the market include - Arcutis Biotherapeutics, Cutanea Life Sciences, Moberg Pharma AB, Astion Pharma A/S, LEO Pharma, Arcutis Biotherapeutics, Maruho Co., Ltd., Kamedis Ltd., Amorepacific Corporation, Moberg Pharma AB, Novartis, Incyte Corporation, and others.
DelveInsight's "Seborrhoeic Dermatitis Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Seborrhoeic Dermatitis, historical and forecasted epidemiology as well as the Seborrhoeic Dermatitis market trends in…
Seborrhoeic Dermatitis Clinical Trials, Companies, Therapeutic Assessment, Thera …
DelveInsight's, "Seborrhoeic Dermatitis - Pipeline Insight, 2025," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Seborrhoeic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
According to DelveInsight, more than five key companies are actively…
Seborrhoeic Dermatitis Market Growth to Accelerate in Forecast Period (2023-2032 …
The Key Seborrhoeic Dermatitis Companies in the market include - Arcutis Biotherapeutics, Cutanea Life Sciences, Moberg Pharma AB, Astion Pharma A/S, LEO Pharma, Arcutis Biotherapeutics, Maruho Co., Ltd., Kamedis Ltd., Amorepacific Corporation, Moberg Pharma AB, Novartis, Incyte Corporation, and others.
DelveInsight's "Seborrhoeic Dermatitis Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Seborrhoeic Dermatitis, historical and forecasted epidemiology as well as the Seborrhoeic Dermatitis market trends in…
Seborrhoeic Dermatitis Clinical Trials | A Drug Pipeline Analysis Report 2024 | …
DelveInsight's 'Seborrhoeic Dermatitis Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Seborrhoeic Dermatitis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Seborrhoeic Dermatitis pipeline domain.
Download our sample report @ https://www.delveinsight.com/report-store/seborrhoeic-dermatitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Key Takeaways from the Seborrhoeic Dermatitis Pipeline Report
Over 5+ Seborrhoeic Dermatitis pipeline therapies are in various stages of development, and their…
Seborrhoeic Dermatitis Clinical Trials | A Drug Pipeline Analysis Report 2024 | …
DelveInsight's 'Seborrhoeic Dermatitis Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Seborrhoeic Dermatitis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Seborrhoeic Dermatitis pipeline domain.
Download our sample report @ https://www.delveinsight.com/report-store/seborrhoeic-dermatitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Key Takeaways from the Seborrhoeic Dermatitis Pipeline Report
Over 5+ Seborrhoeic Dermatitis pipeline therapies are in various stages of development, and their…
Seborrhoeic Dermatitis Market to Witness Upsurge in Growth During the Forecast P …
The Seborrhoeic Dermatitis Market is anticipated to grow in the coming years owing to the potential launch of the pipeline therapiee, the rise in healthcare spending across the world, and the rise in the number of cases of Seborrhoeic Dermatitis in the 7MM. Key players, such as Arcutis Biotherapeutics, Cutanea Life Sciences, and others, are involved in developing drugs for Seborrhoeic Dermatitis.
DelveInsight's " [https://www.delveinsight.com/report-store/seborrhoeic-dermatitis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report delivers an in-depth understanding of…
